With a one year PEG ratio of 2,137.05, Teladoc Health Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 98.08% of US stocks.
The price/operating cash flow metric for Teladoc Health Inc is higher than 98.75% of stocks in our set with a positive cash flow.
TDOC's price/sales ratio is 25.37; that's higher than the P/S ratio of 93.46% of US stocks.
If you're looking for stocks that are quantitatively similar to Teladoc Health Inc, a group of peers worth examining would be HZNP, BL, EXAS, AKAM, and AYX.
Teladoc Health provides telehealth services via mobile devices, the Internet, video, and phone to clients and their customers in the United States. The company was founded in 2002 and is based in Dallas, Texas.
TDOC Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for TDOC, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Teladoc Health Inc ranked in the 99th percentile in terms of potential gain offered. Our DCF model suggests the stock is undervalued by 51956.83%; returns of such proportions should be viewed with some skepticism, though. As for the metrics that stood out in our discounted cash flow analysis of Teladoc Health Inc, consider:
In the past 1 years, Teladoc Health Inc has a compound free cash flow growth rate of 6.42%; that's higher than 97.18% of free cash flow generating stocks in the Technology sector.
The business' balance sheet suggests that 5% of the company's capital is sourced from debt; this is greater than merely 15.51% of the free cash flow producing stocks we're observing.
Teladoc Health Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -1.89. This coverage rate is greater than that of merely 17.08% of stocks we're observing for the purpose of forecasting via discounted cash flows.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
ASX, ZNGA, ALYA, BL, and DCMYY can be thought of as valuation peers to TDOC, in the sense that they are in the Technology sector and have a similar price forecast based on DCF valuation.
A New Syndicate COVID-19 Outbreak-Global Online Doctor Consultation Market Study is added in HTF MI database compiled covering key business segments and wider geographical scope to get deep dive analysed market data. The study brings a perfect bridging between qualitative
On CNBC's "Mad Money Lightning Round," Jim Cramer said Switchback Energy Acquisition Ord Shs Class A (NYSE: SBE ) is another blank-check company. Until we find out more about it, we don't know if we have another Nikola Corporation (NASDAQ: NKLA ), added Cramer. Cramer's … Full story available on Benzinga.com
The telehealth company Teladoc Health Inc (NYSE: TDOC ) has posted strong gains during the coronavirus pandemic. The Teladoc Analyst: D.A. Davidson analyst Hannah Baade initiated coverage of Teladoc with a Buy rating and $250 price target. The Teladoc Thesis: Teladoc, being a pure play software company directly benefiting from COVID-19, is growing at a more than 60% pace organically, Baade said in an initiation note. Telehealth utilization soared to 16% during COVID-19, and it could go up to 25% in the long term, equating to a $250-billion market going forward, the analyst said. Acquisitions have further expanded markets and provided leverage to popular direct-to-consumer … Full story available on Benzinga.com
Summary List Placement American Well raised $742 million ahead of its public market debut, pricing at $18 a share late Wednesday. The stock is set to start trading Thursday morning. As the company goes public, executives including Ido and Roy Schoenberg, the company's founders and CEOs, and investors including Teva Pharmaceuticals stand to make hundreds of millions. The IPO comes on the heels of a huge year for digital health as the coronavirus pandemic fueled Amwell and similar companies to new heights. It's only the second telehealth company to go public, following rival Teladoc's public debut in 2015. SVB Leerink's Stephanie Davis, a healthcare analyst, said the IPO is leading to "the match we've all been waiting for" in an email to investors. But she also said the Teladoc-Amwell riv...